Karl Kieburtz, M.D., MPH, delivered this presentation on asymptomatic gene carriers of Huntington's disease at the sixth World Congress on Huntington's Disease, Rio de Janeiro, Brazil, September 16, 2013. Dr. Kieburtz is the T1 Translation Key Function Director and the director of the Center for Human Experimental Therapeutics (CHET) at the University of Rochester Medical Center (URMC). He is the Robert J. Joynt Professor in Neurology and Professor of Community and Preventive Medicine and Environmental Medicine. CHET conducts learning phase clinical trials in a wide spectrum of disorders in collaboration with investigators within the URMC as well as with colleagues throughout North America, Europe, Asia and Oceania. Dr. Kieburtz's primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson's disease, Huntington's disease, and HIV-related neurologic disorders. He is the principal investigator for the trials of neuroprotective agents for PD (NET-PD) sponsored by the National Institute of Neurological Disorders and Stroke and directs the coordination center for a consortium in neuro-opthalmology funded by the National Eye Institute.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…